Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Marcucci, Guido  [Clear All Filters]
2024
Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T, Moloudizargari M, Pozhitkov A, Singer MK, Dona AAlice, et al. CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNγ-induced CD38 expression. Blood. 2024.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CChyn, Teh T-C, Fong CYew, Ting SB, Weber D, Benner A, et al. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024.
Dong H, He X, Zhang L, Chen W, Lin Y-C, Liu S-B, Wang H, Nguyen LXuan Truon, Li M, Zhu Y, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024.
2023
Zhang B, Zhao D, Chen F, Frankhouser D, Wang H, Pathak KV, Dong L, Torres A, Garcia-Mansfield K, Zhang Y, et al. Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis. Nat Commun. 2023;14(1):5325.
Huang F, Sun J, Chen W, Zhang L, He X, Dong H, Wu Y, Wang H, Li Z, Ball B, et al. Correction: TET2 deficiency promotes MDS-associated leukemogenesis. Blood Cancer J. 2023;13(1):174.
Ngo D, Chen J, Tinajero J, Aribi A, Arslan S, Marcucci G, Nakamura R, Malki MMAl, Forman SJ, Dadwal S, et al. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study. Stem Cell Res Ther. 2023;14(1):95.
Chen Z, Zhou K, Xue J, Small A, Xiao G, Nguyen LXuan Truon, Zhang Z, Prince E, Weng H, Huang H, et al. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. Sci Transl Med. 2023;15(689):eabq8513.
Agrawal V, Pourhassan H, Tsai N-C, Ngo D, Koller P, Malki MMAl, Salhotra A, Ali H, Aribi A, Sandhu KS, et al. Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab. Transplant Cell Ther. 2023.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther. 2023.
2022
Wang H, He X, Zhang L, Dong H, Huang F, Xian J, Li M, Chen W, Lu X, Pathak KV, et al. Disruption of dNTPs Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade. Blood. 2022.
Frankhouser DE, O'Meally D, Branciamore S, Uechi L, Zhang L, Chen Y-C, Li M, Qin H, Wu X, Carlesso N, et al. Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition. Sci Adv. 2022;8(16):eabj1664.
Weng H, Huang F, Yu Z, Chen Z, Prince E, Kang Y, Zhou K, Li W, Hu J, Fu C, et al. The mA reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022.
2021
Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, et al. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. Transplant Cell Ther. 2021.
Qing Y, Dong L, Gao L, Li C, Li Y, Han L, Prince E, Tan B, Deng X, Wetzel C, et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/mA/PFKP/LDHB axis. Mol Cell. 2021.
2020
Huang F, Sun J, Chen W, He X, Zhu Y, Dong H, Wang H, Li Z, Zhang L, Khaled S, et al. HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. Aging (Albany NY). 2020;12.
Xu Y, Payne K, Pham LHoang Gia, Eunwoo P, Xiao J, Chi D, Lyu J, Campion R, Wasnik S, Jeong ISeok, et al. A novel vitamin D gene therapy for acute myeloid leukemia. Transl Oncol. 2020;13(12):100869.
Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, Chen H, Su R, Yin Z, Li W, et al. RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell. 2020.
Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020.
2019
Nakamura R, Gendzekhadze K, Palmer J, Tsai N-C, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. Leuk Res. 2019;87:106230.
2018
Nguyen DQuan, Hoang DHoa, Vo TThao Nguye, Huynh V, Ghoda L, Marcucci G, Nguyen LXuan Truon. The role of ErbB3 binding protein 1 in cancer: Friend or foe?. J Cell Physiol. 2018.
2016
Khaled S, Malki MAl, Marcucci G. Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights. Oncology (Williston Park). 2016;30(4).
Zhang B, Li L, Ho Y, Li M, Marcucci G, Tong W, Bhatia R. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. J Clin Invest. 2016.
2014
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, McCastlain K, Ding L, Lu C, Song G, et al. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. N Engl J Med. 2014;371(11):1005-1015.
2013
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013.